The prognosis of haploidentical hematopoietic stem cell transplantation in infants and patients under 3 years old with acute leukemia.

Abstract

The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients<3 years of age remains controversial. Data on haploidentical donor (HID) transplants in this age group is limited. We retrospectively analyzed the prognosis of 97 patients with acute leukemia aged<3 years who underwent HID transplantation at our institute. With a median follow-up of 45 months, the 3-year disease-free survival (DFS), overall survival (OS), and 3-year cumulative incidence rate of treatment-related mortality were 69.3% (95% confidence interval (CI): 59.9%-78.7%), 74.2% (95% CI: 65.2%-83.2%), and 3.6% (95% CI: 0.9%-9.7%) in all 97 patients, respectively. The 3-year DFS and OS rate in patients diagnosed<1 year and patients diagnosed ≥1 year were comparable: 77.8% (95% CI: 62.2%-93.4%) versus 66.3% (95% CI: 55.0%-77.6%, p=.253) and 82.5% (95% CI: 66.3-98.7%) versus 72.8% (95% CI: 61.9%-83.7%, p=.153), respectively. At the last follow-up, 23 patients had died, and 20 had died of relapse. Multivariate analysis revealed that positive pre-HSCT flow cytometric minimal residual disease (hazard ratio 5.605, p=.000) and AML-M7 expression (hazard ratio 2.906, p=.014) were independent adverse prognostic variables for relapse. HID transplantation is potent and safe for infants and young patients with acute leukemia. Relapse is the primary cause of treatment failure.